insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

TAK · Takeda Pharmaceutical Co Ltd - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue------
Cost of Revenue------
Gross Profit------
R&D------
SG&A------
Total Operating Expenses------
D&A------
Operating Income------
Interest Expense------
Income Tax------
Net Income------
EPS - Basic------
EPS - Diluted------

Balance Sheet

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash & Equivalents------
Accounts Receivable------
Inventory------
Accounts Payable------
Current Assets------
Total Assets------
Current Liabilities------
Long-term Debt------
Total Liabilities------
Stockholders' Equity------
Retained Earnings------

Cash Flow

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Cash Flow------
Investing Cash Flow------
Financing Cash Flow------
CapEx------
Free Cash Flow------

Ratios

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Profitability
Gross margin------
Operating margin------
EBITDA margin------
Net margin------
Free cash flow margin------
FCF / Net income------
R&D / Revenue------
SG&A / Revenue------
Effective tax rate------
Return on assets------
Return on equity------
Return on invested capital------
Liquidity
Current ratio------
Quick ratio------
Cash ratio------
Leverage
Debt / Equity------
Debt / Assets------
Debt / EBITDA------
Interest coverage------
Equity multiplier------
Liabilities / Assets------
Efficiency
Asset turnover------
Inventory turnover------
Days sales outstanding------
Days inventory outstanding------
Days payable outstanding------
Cash conversion cycle------
Valuation
P / E------
P / B------
P / S------
EV / EBITDA------
Growth
Revenue growth (YoY)------
Revenue CAGR (3y)------
Revenue CAGR (5y)------
Gross profit growth (YoY)------
Operating income growth (YoY)------
Net income growth (YoY)------
EPS growth (YoY)------
EPS CAGR (3y)------
EPS CAGR (5y)------
FCF growth (YoY)------
FCF CAGR (5y)------
Book value growth (YoY)------

Stability scores

Piotroski F-score

FY 2025 · 9-point quality

1/9
Weak
  • -Net income positive
  • -Operating cash flow positive
  • -ROA improved YoY
  • -Cash flow > net income
  • -Long-term debt decreased
  • -Current ratio improved
  • ✓No share dilution
  • -Gross margin improved
  • -Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing TAKEDA PHARMACEUTICAL CO LTD against the 5 most active filers in the same SIC group.